UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer.
While the Movember campaign for men's health awareness may technically be over, prostate cancer continues to be a growing concern for men all year long. With prostate cancer being the most common cancer among men, research must continue in order to detect and determine the aggressiveness of tumors, along with having better targeted treatment options available.
Recent exclusive coverage on OncoTherapy Network discusses the newest developments in prostate cancer biomarkers and targeted treatments:
- Prostate Cancer Screening – What Does the Evidence Tell Us?: In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men.
- Reducing Recurrence With a New Prostate Cancer Vaccine: For those patients diagnosed with localized prostate cancer, the risk of recurrence is approximately 30%--even years after initial treatment.
- Prostate Cancer Resistance: Focus on AR-V7: As cancer treatment continues to get more targeted, the search for reliable biomarkers to identify patients most likely to benefit from this novel and expensive therapy is essential.